Cefazolin - Celerity Pharmaceuticals

Drug Profile

Cefazolin - Celerity Pharmaceuticals

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celerity Pharmaceuticals
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Bacterial infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Oct 2015 Registered for Bacterial infections (Prevention) in USA (IV)
  • 14 Aug 2015 Celerity Pharmaceuticals enters into a collaboration with Baxter Healthcare for the development of Cefazolin injection in GALAXY container before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top